An NCI-designated Comprehensive Cancer Center

Tanya Dorff, M.D.

Medical Oncologist
Clinical Expertise
  • Prostate cancer
  • Bladder cancer
  • Testicular cancer
  • Penile cancer
Research Focus
  • Genitourinary malignancies
  • Novel immune-based strategies for prostate cancer
Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research

Clinical Teams

  • Medical Oncology & Therapeutics Research
Tanya Barauskas Dorff, M.D., is an associate clinical professor in the Department of Medical Oncology & Therapeutics Research and serves as head of the genitourinary cancers program at City of Hope. She is an internationally recognized leader in prostate cancer, and is renowned for her work in other genitourinary tumor types, including kidney, bladder and penile cancer.

Dr. Dorff graduated summa cum laude from the University of Houston before attending the UCLA School of Medicine. There, she was inducted into the prestigious Alpha Omega Alpha honors society. She subsequently completed her internal medicine residency at Mt. Sinai Hospital in New York, and finished subspecialty training in hematology and oncology at Los Angeles County + USC Medical Center.
Dr. Dorff remained on the faculty at USC after completing her training, eventually amassing over 70 publications in top-tier journals, including Cancer, Lancet Oncology and Journal of Clinical Oncology. She has been invited to speak at multiple national and international meetings, and serves on the American Society of Clinical Oncology Scientific Committee and the National Cancer Institute Prostate Cancer Task Force.

Dr. Dorff’s research interests in prostate cancer are wide ranging. In the area of clinical trials, she has been heavily involved in the design and conduct of trials related to PSA-recurrent prostate cancer, referring to the setting in which local therapies (e.g., surgery and radiation) fail and blood-based markers (namely PSA) continue to rise. For patients with more advanced prostate cancer, she has studied the role of fasting as it pertains to chemotherapy tolerability, with very compelling early results.
Dr. Dorff leads City of Hope’s joint effort with the Prostate Cancer Foundation to develop novel immune-based strategies for prostate cancer. Specifically, she leads an effort to develop chimeric antigen receptor (CAR) T cells – cells that are primed to target prostate cancer tissue. These strategies have been transformative in certain blood-based cancers. She will also be engaging with laboratory scientists Jeremy Jones, Ph.D., and Marcin Kortylewski, Ph.D., who are developing first-in-human agents to combat prostate cancer through other novel mechanisms.
Dr. Dorff has assumed control of one of the largest clinical trial portfolios in genitourinary cancers, and will be seeing patients with prostate, bladder, testicular and penile cancer.


City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

  • Loh J, Tran A, Ji L, Groshen S, Daneshmand S, Schuckman A, Quinn DI, Dorff TB. Baseline glomerular filtration rate (GFR) and cisplatin-induced renal toxicity in urothelial cancer patients. Clinical GU Cancer 2017; accepted.
  • Pili R, Quinn DI, Hammers HJ, Monk P, George S, Dorff TB, Olencki T, Shen L, Orillion A,  Lamonica D, Fragomeni RS, Szabo Z, Hutson A, Groman A, Perkins SM, Piekarz R, Carducci MA. Immunomodulation by entinostat in renal cell carcinoma patients receiving high dose interleukin 2: a multicenter, single-arm, phase 1/2 trial (NCI-CTEP#7870). Clin Cancer Res 2017; accepted.
  • Alumkai JJ, Chowdhury S, Loriot Y, Sternberg CN, de Bono JS, Tombal B, Carles J, Flaig TW, Dorff TB, Phung, Forer D, Noonberg SB, Manxsbach H, Beer TM, Higano CS. Effect of visceral disease site on outcomes in patients with metastatic castreation-resistant prostate cancer treaqted with  enzalutamide in the PREVAIL trial. Clin Genitourin Cancer 2017; epub PMID 28344102.
  • Dorff TB, Longmate J, Pal SK, Stadler W, Fishman M, Vaishampayan U, Rao A, Pinski J, Hu J, Quinn DI, Lara Jr PN. Bevacizumab alone or in combination with TRC105 for refractory metastatic renal cell cancer patients. Cancer 2017; accepted.
  • Yu SS, Athreya K, Liu SV, Schally AV, Tsao-Wei D, Groshen S, Quinn DI, Dorff TB, Xiong S, Engel J, Pinski J. A Phase II trial of AEZS-108 in castration- and taxane-resistant prostate cancer. Clin Genitourin Cancer 2017; epub PMID 28668277.
  • Wei M, Brandhorst S, Shelehchi M, Mirzaiei H, Cheng CW, Budniak J, Groshen S, Mack WJ, Guen E, Di Biase S, Cohen P, Morgan TE, Dorff T, Hong K, Michalsen A, Laviano A, Longo VD. Fasting-mimicking diet and markers/ risk factors for aging, diabetes, cancer and cardiovascular disease. Sci Transl Med 2017; 9; eaai8700, DOI:10-1126/scitranslmed.aai8700. PMID: 28202779.
  • Abreu A, Fay C, Park D, Quinn D, Dorff T, Carpten J, Kuhn P, Gill P, Almeida F, Gill I. Robotic salvage retroperitoneal and pelvic lymphnode dissection for ‘node-only’ recurrent prostate cancer: technique and initial series. BJU Int 2016; DOI:10.1111/bju.1374 epub.
  • Buonerba C, DiLorenzo G, Pond G, Carteni G, Scagliarini S, Rozzi A, Quevedo FJ, Dorff T, Nappi L, Lanzetta G, Pagliaro L, Eigl BJ, Naik G, Ferro M, dePlacido S, Sonpavde G. Prognostic and predictive factors in patients with advanced penile cancer receiving salvage (2nd or later line) systemic treatment: a retrospective, multi-center study. Frontiers in Pharmacol 2016; 7:4B7. PMID: 28066240.
  • Rini B, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L, Humbert J, Pyle L, Wong Y-N, Finke JH, Rayman PA, Larkin JMG, Garcia JA, Plimack E. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncology 2016; DOI:10.1016/S1470-2045(16)30196-6.
  • Dorff TB, Schuckman AK, Schwartz R*, Rashad S, Bulbul A, Cai J, Pinski J, Ma Y, Danenberg K, Skinner E, Quinn DI. Epidermal growth factor receptor, Excision-repair cross-complementation group 1 protein, and thymidylate synthetase expression in penile cancer. Clin Genitourinary Cancer 2016; 14:450-6.
  • Feldman DR, Hu J, Dorff TB, Lim K, Patil S, Woo KM, Carousso M, Hughes A, Sheinfeld J, Bains M, Daneshmand S, Ketchens C, Bajorin DF, Bosl GJ, Quinn DI, Motzer RJ. Paclitaxel, Ifosfamide, and cisplatin efficacy for first-line treatment of patients with intermediate- or poor-risk germ cell tumors. J Clin Oncol 2016; 34 (21):2478-83. 10.1200/JCO.2016.66.7899.
  • Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, Cheng C-W, Brandhorst S, Cohen P, Wei M, Longo V, Quinn DI. Safety and feasibility of fasting in combination with platinum based chemotherapy. BMC Cancer 2016; 16:360-9.
  • Nussbaum N, George DJ, Abernethy AP, Dolan CM, Oestreicher N, Flanders S, Dorff TB. Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. Prost Cancer Prost Dis 2016; 19:111-21.
  • Barzi A, Klein EA, Dorff TB, Quinn DI, Sadeghi S. Prostatectomy at high-volume centers improves outcomes and lowers the costs of care for prostate cancer. Prost Cancer Prost Dis 2016; 19:84-91.
  • Gross ME, Dorff TB, Quinn DI, Agus DB, Luttgen M, Bethel K, Kolatkar A, Kuhn P. Rapid Changes in circulating tumor cells following anti-angiogenic therapy. Conver Sci Phys Oncol 2015; 1:1-7.
  • Brandhorst S, Choi IY, Wei M, Cheng CW, Sedrakyan S, Navarrete G, Dubeau L, Yap LP, Park R, Vinciguerra M, DiBiase S, Mirzaei H, Mirisola MG, Childress P, Ji L, Groshen S, Penna F, Odetti P, Perin L, Conti PS, Ikeno Y, Kennedy BK, Cohen P, Morgan TE, Dorff TB, Long VD. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan. Cell Metab 2015; 22:86-99.
In The News
An Expert's Voice
Kuk Promo Shot

Kuk Harrell: His caregivers speak

City of Hope News

City of Hope opens chimeric antigen receptor (CAR) T cell trial for advanced prostate cancer

Breakthroughs - prostate cancer clinical trial

PSCA as a novel CAR T target for resistant prostate cancer